Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 180,12 € (+14,11 %). Medianen er 181,94 € (+15,26 %).

Køb
  22
Behold
  2
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Repligen raises forecast and expects growth boost from BioLife takeover

    At the Wells Fargo conference, Repligen reported broader-based growth despite headwinds in areas such as gene therapy and ATF customers. The company said Q2 organic growth was 13% (14% before duty refunds), raised its full-year guidance to 10.5–13.5%, and cited adjusted core growth of about 16%. Management sees drivers in Protein A resins, process analytics, chromatography, a recovery in China/APAC, and opportunities in mRNA, cell therapies and AI-supported instruments. The planned acquisition of BioLife Solutions is expected to deliver economies of scale, lift synergies by $20 million in the first year, and support the path to $1 billion in revenue by 2027 and a 30% EBITDA margin by 2030. » Mere på de.investing.com


  • Repligen raises annual forecast and buys BioLife for $1.5 billion

    Repligen reports significantly better-than-expected quarterly figures with strong order intake. The company has raised its full-year outlook and plans to acquire BioLife for $1.5 billion. Analysts therefore view Repligen as an established market leader in the growing biopharma segment, sparking increased interest from institutional investors. » Mere på finanzen.net


  • Repligen: $100 investment 10 years ago would have grown 391%

    A $100 investment in Repligen ten years ago would today have resulted in 3.339 shares and be worth $491.02, based on a price of $147.06 on August 3, 2026. That corresponds to a gain of 391.02 percent. Repligen’s market capitalization was most recently $7.97 billion. Stock splits and dividends are not included in the calculation. » Mere på finanzen.net


  • Repligen raises full-year guidance after strong Q2 and beats estimates

    Repligen reported adjusted EPS of $0.54 (consensus $0.45) and revenue of $204.1 million (≈+12% year‑over‑year), beating consensus estimates. The company raised its full‑year guidance to an EPS range of $2.03–$2.09 (previous consensus $2.00), citing organic growth and continued order momentum as drivers. Analyst Robert Wasserman upgraded the stock to buy and set a $185 price target. The results come ahead of the planned $1.5 billion acquisition of BioLife Solutions, which would expand Repligen’s share of new modalities to about 25% of pro‑forma revenue. » Mere på de.investing.com


  • Repligen buys BioLife Solutions for $1.5 billion

    Repligen is acquiring BioLife Solutions in a combined cash-and-stock transaction worth about $1.5 billion. BioLife shareholders will receive $11.25 in cash plus 0.1442 Repligen shares (total value $31.00 per share); the consideration is approximately 64% stock and 36% cash. Repligen expects an adjusted earnings contribution of at least $0.05 in year one and $0.25 in year two, and synergies of at least $20 million in year one and $30 million in year two. The transaction is expected to close in Q4 2026, subject to regulatory and shareholder approvals; financing will come from existing cash on hand (pro forma cash after closing expected to be over $300 million). Both companies reported preliminary Q2 figures: Repligen expects about 12% revenue growth, and BioLife forecasts $28.5 million in revenue (+21%). » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde RepliGen en omsætning på 184,79 mio. € og et nettoresultat på -33,93 mio. €
(EUR) september 2026
YoY
Omsætning 184,79 mio. 14,86 %
Bruttofortjeneste 97,98 mio. 14,40 %
Nettoresultat -33,93 mio. 367,03 %
EBITDA -1,74 mio. 104,35 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
10,04 mia. €
Antal aktier
63,92 mio.
Højeste/laveste i 52 uger
180,91 € - 91,87 €
Udbytte Nej
Beta
1,12
P/E (PE Ratio)
-822,24
PEG (PEG Ratio)
1,03
K/I (PB Ratio)
4,67
P/S (PS Ratio)
13,70

Virksomhedsprofil

Repligen Corporation udvikler og kommercialiserer bioprocesteknologier og -systemer til brug i produktionsprocesser for biologiske lægemidler i Nordamerika, Europa, Asien-Stillehavsregionen og internationalt. Virksomheden tilbyder Protein A-ligander, som er bindingskomponenterne i Protein A-affinitetskromatografiharpikser, samt cellekulturvækstfaktorprodukter. Virksomhedens kromatografiprodukter omfatter OPUS præpakkede kromatografikolonner, som anvendes til oprensning af biologiske lægemidler, og OPUS kolonner i mindre skala, der anvendes til high throughput-procesudviklingsscreening, undersøgelser af validering af virusfjernelse og skaleringsvalidering af kromatografiprocesser. Virksomheden tilbyder desuden ELISA-testkits og kromatografiharpikser under mærket CaptivA. Desuden leverer virksomheden filtreringsprodukter, såsom XCell Alternating Tangential Flow-systemer, som er filtreringsenheder, der anvendes i upstream-perfusion og cellekulturprocessering; TangenX flade membran-kassetter, som anvendes i downstream-processer til koncentration og formulering af biologiske lægemidler; KrosFlo tangentialflowfiltrerings- og tangentialflow-dybdefiltreringssystemer; Spectra/Por laboratorie- og procesdialyseprodukter samt SpectraFlo dynamiske dialysesystemer; og ProConnex hule fibre til engangsbrug. Yderligere tilbyder virksomheden procesanalyseprodukter, såsom spektroskopisystemer under mærkerne SoloVPE, FlowVPE og FlowVPX. Virksomheden sælger sine produkter til life science-, biofarmaceutiske og diagnostiske virksomheder, laboratorieforskere og kontraktproduktionsorganisationer. Repligen Corporation har samarbejdsaftaler med Navigo Proteins GmbH om udvikling af flere affinitetsligander. Repligen Corporation blev stiftet i 1981 og har hovedkvarter i Waltham, Massachusetts.

Navn
RepliGen
CEO
Olivier Loeillot
Hjemsted Waltham, ma
USA
Websted
Sektor
Sundhed
Branche
Bioteknologi
Børsnotering
29.04.1986
Medarbejdere 2.000

Tickersymboler

Børs Symbol
NASDAQ
RGEN
Frankfurt
RGN.F
Düsseldorf
RGN.DU
SIX
RGN.SW
München
RGN.MU
🍪

Parqet  bruger cookies. Læs mere